Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
BioInvent International AB (publ) (BINV.ST)
Lund, SE
BioInvent International AB (publ) is a clinical-stage Swedish company dedicated to discovering, researching, and developing immunomodulatory antibodies for global cancer treatment, with reach across Sweden, Europe, the United States, and Japan. Its most advanced therapeutic candidate, BI-1206, targets non-Hodgkin lymphoma and various solid tumors. The company's diverse pipeline also features developments aimed at tumor-associated myeloid cells and cancer-associated regulatory T cells, which play a role in modulating the immune system, alongside BT-001 for solid tumors. Furthermore, BioInvent is progressing BI-1808 and BI-1910, a pair of anti-TNFR2 antibodies, designed to combat solid tumors and cutaneous T-cell lymphoma. Strategic collaborations are integral to its operations; these include a partnership with Pfizer Inc. for antibody development against tumor-associated myeloid cells, a co-development effort with Transgene involving multi-functional oncolytic viruses for solid tumors, and an agreement with Merck for the clinical advancement and supply of BI-1808. Established in 1996, BioInvent is based in Lund, Sweden.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -11.09% | -4.92% | -6.80% | -17.48% | -31.45% | -27.60% | -35.31% | -23.01% | -60.83% | -64.00% | -97.76% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+406.9% ★ Q1'26: -39.2% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+22.5% Q1'26: -2.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-127.8% Q1'26: -994.2% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-155.1% Q1'26: -907.2% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +4,382.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%0.0% ★ Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.03× Q1'26: -0.01× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 3 Rev. Ana. 1 EPS Ana. |
Dec 2028 2 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
15.93M
est: 11.74M (+35.6%)
|
71.28M
est: 84.48M (-15.6%)
|
45.01M
est: 66.22M (-32.0%)
|
38.55M
est: 36.17M (+6.6%)
|
93.74M
est: 84.66M (+10.7%)
|
147.37M
est: 251.04M (-41.3%)
|
19.38M
est: 12.00M (+61.5%)
|
326.13M
est: 310.24M (+5.1%)
|
71.46M
est: 52.67M (+35.7%)
|
44.69M
est: 50.57M (-11.6%)
|
226.50M
est: 236.20M (-4.1%)
|
54.60M
14.18M – 95.01M
-76.9% YoY
|
324.70M
21.88M – 590.65M
+494.7% YoY
|
103.19M
103.18M – 103.19M
-68.2% YoY
|
71.13M
8.50M – 127.87M
-31.1% YoY
|
| EBITDA |
-93.38M
est: -8.26M (-1,030.5%)
|
-61.59M
est: -59.43M (-3.6%)
|
-97.65M
est: -46.59M (-109.6%)
|
-118.10M
est: -25.45M (-364.1%)
|
-126.54M
est: -59.56M (-112.5%)
|
-63.99M
est: -176.60M (+63.8%)
|
-263.32M
est: -8.44M (-3,019.2%)
|
-27.13M
est: -218.25M (+87.6%)
|
-312.71M
est: -43.01M (-627.0%)
|
-409.39M
est: -41.29M (-891.4%)
|
-331.52M
est: -192.89M (-71.9%)
|
-44.58M
-77.59M – -11.58M
+76.9% YoY
|
-265.17M
-482.34M – -17.87M
-494.7% YoY
|
-84.27M
-84.27M – -84.26M
+68.2% YoY
|
-58.09M
-104.43M – -6.94M
+31.1% YoY
|
| EBIT |
-95.03M
est: -8.56M (-1,010.5%)
|
-62.59M
est: -61.57M (-1.6%)
|
-100.52M
est: -48.26M (-108.3%)
|
-123.16M
est: -26.36M (-367.2%)
|
-138.15M
est: -61.70M (-123.9%)
|
-76.00M
est: -182.96M (+58.5%)
|
-277.93M
est: -8.75M (-3,077.9%)
|
-41.85M
est: -226.10M (+81.5%)
|
-329.46M
est: -43.49M (-657.6%)
|
-428.69M
est: -41.75M (-926.8%)
|
-351.39M
est: -195.02M (-80.2%)
|
-45.08M
-78.44M – -11.71M
+76.9% YoY
|
-268.10M
-487.68M – -18.06M
-494.7% YoY
|
-85.20M
-85.20M – -85.20M
+68.2% YoY
|
-58.73M
-105.58M – -7.02M
+31.1% YoY
|
| Net Income |
-90.68M
est: -858.36M (+89.4%)
|
-62.59M
est: -274.36M (+77.2%)
|
-100.53M
est: -412.30M (+75.6%)
|
-123.16M
est: -590.37M (+79.1%)
|
-139.12M
est: -435.33M (+68.0%)
|
-76.67M
est: 452.42M (-116.9%)
|
-278.96M
est: -398.40M (+30.0%)
|
-34.09M
est: -63.39M (+46.2%)
|
-330.30M
est: -383.48M (+13.9%)
|
-429.38M
est: -291.96M (-47.1%)
|
-332.86M
est: -335.45M (+0.8%)
|
-274.35M
-986.15M – 70.04M
+18.2% YoY
|
-226.42M
-487.45M – 34.62M
+17.5% YoY
|
-215.00M
-301.63M – 21.42M
+5.0% YoY
|
—
— – —
+100.0% YoY
|
| SGA |
31.65M
est: 10.41M (+204.1%)
|
35.72M
est: 74.88M (-52.3%)
|
39.26M
est: 58.70M (-33.1%)
|
27.96M
est: 32.06M (-12.8%)
|
29.09M
est: 75.04M (-61.2%)
|
31.64M
est: 222.50M (-85.8%)
|
39.44M
est: 10.64M (+270.8%)
|
50.75M
est: 274.98M (-81.5%)
|
51.61M
est: 47.85M (+7.9%)
|
58.30M
est: 45.94M (+26.9%)
|
73.67M
est: 214.58M (-65.7%)
|
49.60M
12.89M – 86.31M
-76.9% YoY
|
294.98M
19.88M – 536.58M
+494.7% YoY
|
93.74M
93.74M – 93.75M
-68.2% YoY
|
64.62M
7.72M – 116.17M
-31.1% YoY
|
| EPS |
-16.00
est: -13.04 (-22.7%)
|
-6.18
est: -4.17 (-48.2%)
|
-8.08
est: -6.27 (-29.0%)
|
-9.07
est: -8.97 (-1.1%)
|
-7.53
est: -6.62 (-13.8%)
|
-2.67
est: 6.88 (-138.8%)
|
-5.15
est: -6.05 (+14.9%)
|
-0.55
est: -0.96 (+42.9%)
|
-5.02
est: -5.82 (+13.8%)
|
-6.53
est: -3.93 (-66.3%)
|
-5.06
est: -4.97 (-1.9%)
|
-7.36
-14.99 – 1.06
-48.2% YoY
|
-3.64
-7.41 – 0.53
+50.6% YoY
|
-2.25
-4.59 – 0.33
+38.1% YoY
|
—
— – —
+100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - International Core Equity 2 ETF DFIC | 0.00% | 47.1K | 0.22% |
| 2 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 38.7K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Martin Welschof | President & Chief Executive Officer | 5M | — |
| Björn Frendéus | Chief Scientific Officer | 2M | male |
| Cecilia Hofvander | Vice President of Investor Relations | — | female |
| Ingrid Teige | Head of Preclinical Research | — | female |
| Ingunn Munch Lindvig | Senior Vice President of Regulatory Affairs | — | — |
| Kristoffer Rudenholm Hansson | Senior Vice President of Technical Operations | — | male |
| Marie Moores | Chief Operating Officer | — | female |
| Stefan Ericsson | Chief Financial Officer | — | male |
| Andres McAllister | Chief Medical Officer | — | — |
| Sylvie Ryckebusch | Chief Business Officer | — | female |
| Ashley R. Robinson | Senior VP of Strategy & Finance | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BINV.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
